First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study.

Niels Andreasen, Monica Simeoni, Henrik Östlund, Pia I Lisjo, Tormod Fladby, Amy E Loercher, Gerard J Byrne, Frances Murray, Paul T Scott-Stevens, Anders Wallin, Yinghua Y Zhang, Lena H Bronge, Henrik Zetterberg, Agneta K Nordberg, Astrid J Yeo, Shahid A Khan, Jan Hilpert, Prafull C Mistry

Research output: Contribution to journalArticlepeer-review

27 Citations (SciVal)

Abstract

To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Fc-inactivated anti-β amyloid (Aβ) monoclonal antibody (mAb) GSK933776 in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI).
Original languageEnglish
Article numbere0098153
JournalPLoS ONE
Volume10
Issue number3
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Neurology

Fingerprint

Dive into the research topics of 'First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study.'. Together they form a unique fingerprint.

Cite this